2. Neuronal Signaling Protein Tyrosine Kinase/RTK Apoptosis
  3. Trk Receptor c-Fms PDGFR Bcr-Abl c-Kit Apoptosis
  4. IHMT-TRK-284

IHMT-TRK-284 (Compound 34) 是一种有效的、具有口服活性的 type II TRK kinase 抑制剂，对 TRKA, B, C 的 IC50 值分别为 10.5, 0.7 和 2.6 nM。 IHMT-TRK-284 在激酶组中表现出良好的选择性、具有良好的体内抗肿瘤效果。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

IHMT-TRK-284 Chemical Structure

IHMT-TRK-284 Chemical Structure

CAS No. : 2416844-79-4

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

IHMT-TRK-284 相关抗体

Top Publications Citing Use of Products

查看 Trk Receptor 亚型特异性产品:

查看所有亚型
TrkA TrkB TrkC Trk

查看 PDGFR 亚型特异性产品:

查看所有亚型
PDGFR PDGFRβ PDGFRα

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

IHMT-TRK-284 (Compound 34) is a potent, orally active type II TRK kinase inhibitor with IC50 values of 10.5, 0.7, and 2.6 nM to TRKA, B, and C respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies[1].

IC50 & Target

TrkB

0.7 nM (IC50)

TrkC

2.6 nM (IC50)

TrkA

10.5 nM (IC50)

CSF1R

1.2 nM (IC50)

PDGFRα

24.2 nM (IC50)

PDGFRβ

95.7 nM (IC50)

Abl1

83.6 nM (IC50)

KIT

2167 nM (IC50)

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
BaF3 GI50
1.4 μM
Compound: 34
Antiproliferative activity in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
Antiproliferative activity in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay
[PMID: 32949955]
体外研究
(In Vitro)

IHMT-TRK-284 (Compound 34) (0-10 µM, 72 h) shows antiproliferative effects against BaF3 cells, a panel of kinase transformed BaF3 cells, and KM-12-LUC cells[1].
IHMT-TRK-284 (0-10 µM, 24 h) induces apoptosis and arrests the cell cycle into G0/G1 phase in KM-12-LUC cells[1].
IHMT-TRK-284 exerts its inhibitory effect to the colon cancer cells through on-target inhibition of TRK[1].
IHMT-TRK-284 could overcome drug resistant mutants including V573M and F589L in the ATP binding pocket as well as G667C/S in the DFG region[1].
IHMT-TRK-284 shows selectivity over VEGFR2 kinase[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

IHMT-TRK-284 相关抗体:

Cell Proliferation Assay[1]

Cell Line: BaF3 cells, a panel of kinase transformed BaF3 cells, and KM-12-LUC cells
Concentration: 0-10 µM
Incubation Time: 72 h
Result: Showed antiproliferative effects against BaF3 cells, a panel of kinase transformed BaF3 cells, and KM-12-LUC cells. GI50 for KM-12-LUC cells was 0.002 µM.
Antiproliferative effects of IHMT-TRK-284 against a panel of kinase transformed BaF3 cells[1].
Target BaF3-TEL-ABL BaF3-TEL-CSF1R BaF3-TEL-KIT BaF3-TEL-PDGFRα BaF3-TEL-PDGFRβ BaF3-TEL-TRKA BaF3-TEL-TRKB BaF3-TEL-TRKC
GI50 (nM) 411.1 4 923.2 1.7 1.4 8.5 8.2 27.3

Antiproliferative effects of IHMT-TRK-284 against a panel of TRKs wt/mutants transformed BaF3 cells (n = 3)[1].
Showed antiproliferative effects with GI50s of 1.4 ± 0.011, 0.007 ± 0.001, 0.003 ± 0.001, 0.004 ± 0.001, 0.194 ± 0.013, 0.034 ± 0.002, 0.002 ± 0.001 μM against BaF3, BaF3-LMNA-TRKA, BaF3-LMNA-TRKA-V573M, BaF3-LMNA-TRKA-F589L, BaF3-LMNA-TRKA-G595R, BaF3-LMNA-TRKA-G667C, BaF3-LMNA-TRKA-G667S cells, respectively.

Western Blot Analysis[1]

Cell Line: BaF3-TEL-TRKA, BaF3-TEL-TRKB, BaF3-TEL-TRKC, BaF3-LMNATRKA-V573M, BaF3-LMNA-TRKA-F589L, BaF3-LMNA-TRKA-G595R, BaF3-LMNA-TRKA-G667C/S, and KM-12-LUC cells
Concentration: 0, 0.01, 0,03, 0.1, 0.3, 1, 3, and 10 µM
Incubation Time: 2 h
Result: In transformed BaF3 cells: Inhibited the phosphorylation of TRKA Y490 (EC50 = 0.026 µM) and corresponding tyrosine residues TRKB Y515 (EC50 = 0.069 µM) and TRKC Y516 (EC50 = 0.029 µM); potently inhibited the phosphorylation of Y490 in V573M, F589L, and G667C/S mutants with EC50s of 0.013 µM, 0.021 µM, 0.067 µM, and 0.074 µM respectively. In KM-12-LUC cells: Blocked the phosphorylation of TRKA Y490 at the concentration of 0.01 µM; remarkably inhibited the phosphorylation of downstream signaling mediators AKT T308/S473 and ERK1/2 (T202/Y204) (EC50 less than 0.03 µM).

Apoptosis Analysis[1]

Cell Line: KM-12-LUC cells
Concentration: 0, 0.01, 0,03, 0.1, 0.3, 1, 3, and 10 µM
Incubation Time: 24 h
Result: Induced dose-dependent cell apoptotic death.

Cell Cycle Analysis[1]

Cell Line: KM-12-LUC cells
Concentration: 0, 0.01, 0,03, 0.1, 0.3, 1, 3, and 10 µM
Incubation Time: 24 h
Result: Arrested the cell cycle into G0/G1 phase.
体内研究
(In Vivo)

IHMT-TRK-284 (Compound 34) (40 and 80 mg/kg; p.o.; daily, 10 days) shows good in vivo PK and antitumor efficacy properties[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Four-week old female nu/nu mice, one million BaF3-TELTRKA, BaF3-TEL-TRKB, BaF3-TEL-TRKC, BaF3-LMNA-TRKA-F589L, BaF3-LMNA-TRKA-G667S, and five million KM-12-LUC cells in DMEM medium were formulated as a 1:1 mixture with matrigel and injected into the subcutaneous space on the right flank of nu/nu mice[1]
Dosage: 40 mg/kg and 80 mg/kg
Administration: Daily oral gavage, 10 days
Result: Dose-dependently inhibited the BaF3-TEL-TRKA, BaF3-TEL-TRKB, and BaF3-TEL-TRKC tumor progression with TGI (tumor growth inhibition) of 68%, 93%, and 58%. Dose-dependently inhibited the tumor progression and exhibited the TGI of 93% at 40 mg/kg/day and 95% at 80 mg/kg/day in KM-12-LUC cells inoculated xenograft mouse model. Potently inhibited the tumor growth with TGI values of 88% and 89% respectively at 80 mg/kg dosage in BaF3- LMNA-TRKA-F589L and BaF3-LMNA-TRKA-G667S cells.
Animal Model: Mice, sprague dawley rats, and beagle dogs[1]
Dosage: 1 mg/kg and 10 mg/kg
Administration: Intravenous injection and oral administration (Pharmacokinetic Analysis)
Result: Pharmacokinetic study of IHMT-TRK-284 in mice, sprague dawley rats, and beagle dogsa[1]
Parameter Mice
i.v. (1 mg/kg)		 Mice
p.o. (10 mg/kg)		 Rats
i.v. (1 mg/kg)		 Rats
p.o. (10 mg/kg)		 Beagle Dogs
i.v. (1 mg/kg)		 Beagle Dogs
p.o. (10 mg/kg)
AUC(0-t)
(ng/mL*h)		 748 1431 393 952 323 464
Tmax (h) 0.033 1.5 0.03 4.7 0.08 4.3
T1/2 (h) 2.6 3.4 2.7 2.5 0.03 11.8
Vz (mL/kg) 4934 31567 9682
分子量

473.59

Formula

C25H27N7OS
CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

IHMT-TRK-284 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

IHMT-TRK-2842416844-79-4Trk Receptorc-FmsPDGFRBcr-Ablc-KitApoptosisTropomyosin related kinase receptor CSF-1 receptorcolony stimulating factor 1 receptorCSF-1RCSF1RPlatelet-derived growth factor receptorSCFRCD117SelectivityAntitumorBaF3KM-12-LUCInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
IHMT-TRK-284
目录号：
HY-146697
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.